0 382

Cited 11 times in

Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors

DC Field Value Language
dc.contributor.author신상준-
dc.date.accessioned2022-02-23T01:03:27Z-
dc.date.available2022-02-23T01:03:27Z-
dc.date.issued2021-09-
dc.identifier.issn0960-894X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187518-
dc.description.abstractAs DYRK1A and 1B inhibitors, 1H-pyrazolo[3,4-b]pyridine derivatives were synthesized. Mostly, 3-aryl-5-arylamino compounds (6) and 3,5-diaryl compounds (8 and 9) were prepared and especially, 3,5-diaryl compound 8 and 9 showed excellent DYRK1B inhibitory enzymatic activities with IC50 Values of 3-287 nM. Among them, 3-(4-hydroxyphenyl), 5-(3,4-dihydroxyphenyl)-1H-pyrazolo[3,4-b]pyridine (8h) exhibited the highest inhibitory enzymatic activity (IC50 = 3 nM) and cell proliferation inhibitory activity (IC50 = 1.6 µM) towards HCT116 colon cancer cells. Also compound 8h has excellent inhibitory activities in patient-derived colon cancer organoids model as well as in 3D spheroid assay model of SW480 and SW620. The docking study supported that we confirmed that compound 8h binds to DYRK1B through various hydrogen bonding interactions and hydrophobic interactions.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherPergamon Press-
dc.relation.isPartOfBIOORGANIC & MEDICINAL CHEMISTRY LETTERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntineoplastic Agents / chemical synthesis-
dc.subject.MESHAntineoplastic Agents / chemistry-
dc.subject.MESHAntineoplastic Agents / pharmacology*-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Proliferation / drug effects-
dc.subject.MESHCell Survival / drug effects-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHDrug Screening Assays, Antitumor-
dc.subject.MESHHumans-
dc.subject.MESHMolecular Structure-
dc.subject.MESHProtein Kinase Inhibitors / chemical synthesis-
dc.subject.MESHProtein Kinase Inhibitors / chemistry-
dc.subject.MESHProtein Kinase Inhibitors / pharmacology*-
dc.subject.MESHProtein Serine-Threonine Kinases / antagonists & inhibitors*-
dc.subject.MESHProtein Serine-Threonine Kinases / metabolism-
dc.subject.MESHProtein-Tyrosine Kinases / antagonists & inhibitors*-
dc.subject.MESHProtein-Tyrosine Kinases / metabolism-
dc.subject.MESHPyrazoles / chemical synthesis-
dc.subject.MESHPyrazoles / chemistry-
dc.subject.MESHPyrazoles / pharmacology*-
dc.subject.MESHPyridines / chemical synthesis-
dc.subject.MESHPyridines / chemistry-
dc.subject.MESHPyridines / pharmacology*-
dc.subject.MESHStructure-Activity Relationship-
dc.titleSynthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorAreum Park-
dc.contributor.googleauthorJieon Hwang-
dc.contributor.googleauthorJoo-Youn Lee-
dc.contributor.googleauthorEun Ji Heo-
dc.contributor.googleauthorYoon-Ju Na-
dc.contributor.googleauthorSein Kang-
dc.contributor.googleauthorKyu-Sung Jeong-
dc.contributor.googleauthorKi Young Kim-
dc.contributor.googleauthorSang Joon Shin-
dc.contributor.googleauthorHyuk Lee-
dc.identifier.doi10.1016/j.bmcl.2021.128226-
dc.contributor.localIdA02105-
dc.relation.journalcodeJ00326-
dc.identifier.eissn1464-3405-
dc.identifier.pmid34182093-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0960894X21004534?via%3Dihub-
dc.subject.keywordColon cancer-
dc.subject.keywordDYRK1A-
dc.subject.keywordDYRK1B-
dc.subject.keywordKinase Inhibitors-
dc.subject.keywordOrganoid-
dc.subject.keywordPyrazolopyridines-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.affiliatedAuthor신상준-
dc.citation.volume47-
dc.citation.startPage128226-
dc.identifier.bibliographicCitationBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol.47 : 128226, 2021-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.